EUCTR2018-002443-28-IT进行中（未招募）1 期
A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator's Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia without del(17p) or TP53 Mutation. - Not available at this time
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 780
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Men and women =18 years of age.
- •2. Eastern Cooperative Oncology Group (ECOG) performance status of 0–2.
- •3. Diagnosis of CLL that meets published diagnostic criteria (Hallek et al. 2018):
- •a. Monoclonal B-cells (either kappa or lambda light chain restricted) that are clonally co-expressing B-cell marker (CD19, CD20, and CD23) and CD5.
- •b. Prolymphocytes may comprise <55% of blood lymphocytes.
- •c. Presence of =5x109 B lymphocytes/L (5000/µL) in the peripheral blood (at any point since the initial diagnosis).
- •4. Active disease per IWCLL 2018 criteria that requires treatment (see Section 4.5.6).
- •5. Meet the following laboratory parameters: a) Adequate bone marrow function independent of growth factor or transfusion support within 1 week of Screening, as follows:
- •i. ANC =750 cells/µL (0.75x109/L); ANC =500 cells/µL (0.50x109/L) in subjects with documented bone marrow involvement of CLL
- •ii. Platelet count =50,000 cells/µL (50x109/L); platelet count =30,000 cells/µL (30x109/L) in subjects with documented bone marrow involvement of CLL
- •b) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5xULN.
- •c) Total bilirubin =2xULN, unless directly attributable to Gilbert's syndrome
- •d) Estimated creatinine clearance of =50 mL/min, calculated using the formula of Cockcroft and Gault (if male, [140Age] x Mass (kg) / [72 x creatinine mg/dL]; multiply by 0.85 if female); estimated creatinine clearance of =70 mL/min for subjects selected by investigator to receive FCR in Arm C
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 280
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 500
排除标准
- •1. Any prior CLL-specific therapies (except corticosteroid treatment administered due to necessary immediate intervention; within the last 10 days before start of study treatment, only dose equivalents up to 20 mg prednisone daily are permitted).
- •2. Detected del(17p) or TP53 mutation.
- •3. Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL) (e.g., Richter's transformation, PLL, or diffuse large B cell lymphoma [DLBCL]), or central nervous system (CNS) involvement by leukemia.
- •4. Any comorbidity or organ system impairment rated with a single CIRS score of 4 (excluding the eyes/ears/nose/throat/larynx organ system), or a total CIRS score of >6.
- •5. Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura.
- •6. History of confirmed progressive multifocal leukoencephalopathy (PML).
- •7. Received any investigational drug within 30 days before first dose of study drug.
- •8. Major surgical procedure within 30 days before the first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug.
- •9. History of prior malignancy that could affect compliance with the protocol, or interpretation of results, except for the following:
- •a. Curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or carcinoma in situ of the prostate at any time prior to study.
- •b. Other cancers not specified above which have been curatively treated by surgery and/or radiation therapy from which subject is disease-free for =3 years without further treatment.
研究者
相似试验
进行中（未招募）
1 期
A Clinical trial to compare Acalabrutinib (ACP-196) versus investigator's choice standard treatment with Bendamustine/Rituximab or Idelalisib/Rituximab alone in patients with with Relapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Chronic Lymphocytic LeukemiaMedDRA version: 20.1Level: LLTClassification code 10008978Term: Chronic lymphocytic leukemia refractorySystem Organ Class: 100000004864EUCTR2015-004454-17-HRAcerta Pharma BV306
进行中（未招募）
1 期
Study of chemotherapy (Gemcitabine+cisplatin) with and without the new drug IMC-11F8 (Necitumumab) in patients with advanced lung cancerEUCTR2009-013838-25-HUImClone LLC1,080
进行中（未招募）
1 期
A Clinical trial to compare Acalabrutinib (ACP-196) versus investigator's choice standard treatment with Bendamustine/Rituximab or Idelalisib/Rituximab alone in patients with with Relapsed or Refractory Chronic Lymphocytic LeukemiaEUCTR2015-004454-17-DEAcerta Pharma BV306
进行中（未招募）
1 期
A Clinical trial to compare Acalabrutinib (ACP-196) versus investigator's choice standard treatment with Bendamustine/Rituximab or Idelalisib/Rituximab alone in patients with with Relapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Chronic Lymphocytic LeukemiaMedDRA version: 21.1Level: LLTClassification code 10008978Term: Chronic lymphocytic leukemia refractorySystem Organ Class: 100000004864EUCTR2015-004454-17-BEAcerta Pharma BV306
进行中（未招募）
1 期
Study to compare how long subjects with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving chemotherapy aloneGastric or Gastroesophageal Junction CancerMedDRA version: 21.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001018-76-PTBristol-Myers Squibb International Corporation3,200